Multiple myeloma
(Plasma Cell Myeloma)

  • Method:
  • Anticoagulant:
  • Recommendation:
  • Method:
    Cytomorphology
  • Anticoagulant:
    EDTA
  • Recommendation:
    obligatory
  • Method:
    Immunophenotyping
  • Anticoagulant:
    EDTA or Heparin
  • Recommendation:
    facultative
  • Method:
    Chromosome analysis
  • Anticoagulant:
  • Recommendation:
    no
  • Method:
    FISH
  • Anticoagulant:
    EDTA or Heparin
  • Recommendation:
    obligatory*
  • Method:
    Molecular genetics
  • Anticoagulant:
    EDTA or Heparin
  • Recommendation:
    facultative

* after CD138+ sorting

Multiple myeloma (MM), also known as plasma cell myeloma, can be classified within plasma cell neoplasm. In addition to classification and diagnostics, we will also present therapy options and prognoses for multiple myeloma.

Definition and characteristics

Plasma cell myeloma (according to WHO) or multiple myeloma (MM) is characterized by a malignant plasma cell proliferation in the bone marrow and is accompanied by an increased production of monoclonal immunoglobulins, which are usually detectable in serum as M-gradient.

The diagnosis of suspected or confirmed multiple myeloma is complex and includes not only cytomorphology but also histology, imaging techniques, serum and urine tests such as immunofixation or immunoelectrophoresis and determination of the light chains of immunoglobulins. In addition, genetic methods - currently primarily FISH analysis of cell fractions previously enriched by separation to CD138 positive plasma cells - are of great importance for prognostic classification. Immunophenotyping can also provide valuable information in many cases, since it can detect aberrant expression patterns on the plasma cells, and thus monoclonality, with high sensitivity. It is the most important technique for MRD. Molecular genetic studies are gaining increasing importance with regard to additional prognostic information (e.g. TP53 mutation) or the use of targeted therapies (e.g. BRAF mutation).

Classification of the Multiple Myeloma

According to the WHO classification 2017, multiple myeloma belongs to the group of plasma cell neoplasms within mature B-cell neoplasms.


Multiple Myeloma WHO-Classification 2017
(Swerdlow et al. 2017)

Mature B-cell neoplasm

  • Plasma cell neoplasms
    • Plasma cell myeloma (multiple myeloma)

Depending on the concentration of the M protein in the serum and the proportion of plasma cells in the bone marrow, the asymptomatic phases "monoclonal gammopathy of undetermined significance" (MGUS) and "smoldering multiple myeloma" (SMM) are distinguished. A transition to symptomatic myeloma occurs in patients with MGUS with a probability of approximately 1% per year, while the risk of progression in patients with SMM is 10% per year in the first 5 years.

Risk classification according to International Staging System (ISS), lactate dehydrogenase and FISH

To identify the risk group, a combination of the International Staging System (ISS; see Table 1), lactate dehydrogenase in serum and cytogenetics using FISH is recommended (Moreau et al. 2017). For cytogenetic diagnostics, the International Myeloma Working Group recommends at least the performance of FISH analyses for the detection of the 17p deletion and the translocation t(4;14). Analyses for the detection of 1q gains and 1p deletions as well as t(14;16) and t(14;20) represent a useful extension for risk stratification (Sonneveld et al. 2016).

25%

of MM-patients have no symptoms at diagnosis

(Oncopedia guideline multiple myeloma)

Table 1: International Staging System and risk factors

(ESMO-Guidelines: Moreau et al. 2017)

International Staging System (ISS) (P. Greipp et al. 2005)

Stage

Criteria

I

Serum ß2M <3,5 mg/l and serum albumin ≥3,5 g/dl

II

Not Stage I or III

III

Serum ß2M ≥5,5 mg/l


High risk

Standard risik

LDH

> ULN

 < ULN

Cytogenetics according to Palumbo et al. 2015

t(4;14), t(14;16), del(17p)

all others

Cytogenetics according to Sonneveld et al. 2016

t(4;14), t(14;16), del(17p),
t(14;20), 1q gain

all others including
t(11;14), t(6;14)

β2M = β2 microglobulin, LDH = lactat dehydrogenase, ULN = upper limit of normal

Previous risk stratification models only consider the detection of certain aberrations, but not their interaction. A recently developed weighted index integrating six prognostically relevant changes ((t(4;14), del(17p), trisomy 5, trisomy 21, 1q gain, del(1p32)) achieved a higher prediction accuracy than the ISS (Perrot et al. 2019) and shows potential for improvement of the previous risk stratifications.

In addition, it was shown that gene expression analyses are of high prognostic relevance for patients with multiple myeloma and that the combination of gene expression profiles with the ISS represents a significant prognostic factor (Shaughnessy et al. 2007, Kuiper et al. 2015). In the foreseeable future, molecular markers will also become routine; BRAF mutations already have therapeutic relevance.

Multiple Myeloma - Diagnostics

Multiple Myeloma - Prognosis

Multiple myeloma with hyperdiploidy is the most prognostically favorable subtype

The favourable prognosis for patients with multiple myeloma with a hyperdiploid set of chromosomes has recently been confirmed. Thus, a clear advantage in survival analysis was shown for this MM subtype compared to all other cytogenetic subgroups. Even for patients with the translocation t(11;14)(q13;q32), which is also assigned to the standard risk group, a less favourable prognosis was shown than for patients with hyperdiploidy (Lakshman et al. 2018, Shah et al. 2018).

IGH rearrangements have different prognostic significance

The most frequent translocation partners of the IGH locus in multiple myeloma are CCND1 (11q13), FGFR3 (4p16), MAF (16q23), MAFB (20q12) and CCND3 (6p21). Table 3 shows the prognostic significance of the various IGH rearrangements.

Table 3: Prognosis and incidence of frequent IGH rearrangements

Translocation

Prognosis

Incidence

t(4;14)(p16;q32)
IGH-FGFR3-rearrangement

poor

11-15%

t(14;16)(q32;q23)
IGH-MAF-rearrangement

poor

3-6%

t(14;20)(q32;q12)
IGH-MAFB-rearrangement

poor

1-2%

t(11;14)(q13;q32)
IGH-CCND1-rearrangement

favourable

14-20%

t(6;14)(p21;q32)
IGH-CCND3-rearrangement

favourable

<1-4%


(Bacher et al. 2010, Sawyer et al. 2011, Morgan et al. 2012, Sonneveld et al. 2016).

Prognosis of frequent structural aberrations: Gains, deletions and MYC rearrangements

The prognostic significance of the most frequent structural aberrations is summarized in Table 4.

Gains

1q Gains are associated with disease progression and a shorter survival time (Avet-Loiseau et al. 2012, Shah et al. 2018, Perrot et al. 2019). In the literature there is controversial discussion whether 1q amplification additionally worsens the prognosis (Walker et al. 2015, Shah et al. 2018, Walker et al. 2019). The definition of the number of copies from which amplification is present differs between the sources - which further limits the comparability of the studies. Since even high-dose therapy protocols and/or drugs of new substance classes do not improve the prognosis for 1q gains, a therapy approach similar to that for patients with a different high-risk aberration should be considered for these patients (Kumar & Rajkumar 2018).

Deletions

1p deletions are associated with an unfavourable prognosis, whereby the prognosis is more unfavourable for a 1p32 region deletion than for a 1p22 region deletion (Hebraud et al. 2013 and 2015, Shah et al. 2018, Perrot et al. 2019).

The published association of 13q deletions detected by FISH with an unfavorable prognosis is based on the abundance of the region together with the unfavorable aberrations t(4;14) and del(17p) (Fonseca et al. 2009, Neben et al. 2010 and 2012). In contrast, del(13q) detected by conventional chromosome analysis is associated with a less favourable prognosis (Chiecchio et al. 2006).

17p deletions are associated with an unfavorable prognosis (An et al. 2015, Shah et al. 2018, Perrot et al. 2019), whereby it is discussed from which clone size on the negative influence becomes effective (An et al. 2015). 17p deletions may also include the TP53 gene. If a biallelic TP53 inactivation results from a deletion or mutation of the second allele, this further worsens survival (Weinhold et al. 2016, Walker et al. 2018 and 2019, Thakurta et al. 2019).

MYC rearrangements and amplifications

Rearrangements and amplifications of the MYC gene usually occur at a later stage and are associated with an unfavourable prognosis - this aberration is observed in approximately 45% of patients with advanced multiple myeloma (Morgan et al. 2012, Walker et al. 2014).

Table 4: Prognosis and incidence of various structural aberrations in multiple myeloma

Aberration

Prognosis

Incidence

1q gain

poor

36-49%

1p deletion

poor

30%

13q deletion

-

45-58%

17p deletion

poor

7-13%

MYC-rearrangement

poor

5-15%

6q deletion

-

33%

8p deletion

-

23-25%

11q gain

favourable

24%

12p deletion

poor

15%

16q deletion

poor

20-35%


(Munshi et al. 2011, Avet-Loiseau et al. 2011, Avet-Loiseau et al. 2012, Morgan et al.  2012, Neben et al. 2012, Avet-Loiseau et al. 2013, An et al. 2015)

Prognostic relevance of trisomies in high risk aberrations unclear

Whether the presence of trisomies improves the prognosis of patients with simultaneous 17p deletion, t(4;14), t(14;16) or t(14;20) is controversially discussed. The contradictory results are probably due, among other things, to the different treatment protocols used in the studies (Kumar et al. 2012, Pawlyn et al. 2015). In addition, a divergent prognostic effect was described for individual trisomies. While trisomies of chromosomes 3 and 5 have a positive influence on survival, trisomy 21 leads to a worsening of the prognosis (Chretien et al. 2015, Perrot et al. 2019).

Combined occurrence of unfavourable aberrations worsens prognosis

According to Sonneveld et al., prognostically unfavorable aberrations include the translocations t(4;14), t(14;16), t(14;20), the 1q gain and the 17p deletion (Sonneveld et al. 2016). If t(4;14) or del(17p) occurs, the prognosis worsens regardless of the ISS stage (Avet-Loiseau et al. 2013).

For the aberrations mentioned above, it has been shown that the negative influence on the course of the disease is less when they occur alone than when several of these aberrations occur simultaneously (Boyd et al. 2012, Shah et al. 2018).

Shah et al. speak in this context of the "double-hit". Table 5 shows the survival as a function of the number (0-2) of prognostically unfavourable aberrations for MM patients in the Myeloma XI study. While three unfavourable aberrations were detected, median overall survival was only 19 months (Shah et al. 2018).

Table 5: Survival of patients with multiple myeloma according to number of prognostically unfavourable aberrations (t(4;14), t(14;16), t(14;20), 1q gain, del(17p)) in a myeloma XI study cohort

(Shah et al. 2018)

Survival analysis of 1036  MM patients of the Myeloma XI studyNo adverse lesions

One adverse lesion

Double-hit (two adverse lesions)

Median progression free survival

31.1 months

24.2 months

17 months

Median overall survival after 24 months

86.4%

76.6%

66.1%

The occurrence of subclones in patients with high risk aberrations worsens the prognosis

Clonal heterogeneity is characteristic of multiple myeloma and the occurrence of subclones has prognostic relevance. Overall survival is further worsened if subclones are detected in addition to a high-risk aberration (del(17p), 1q gain, t(4;14)). In patients of the standard risk group, however, the presence of subclones has no prognostic influence (Merz et al. 2018).

In the course of therapy and disease, MRD negativity and the duration of recurrence-free survival are important prognostic factors

The prognostic factors mentioned so far have been validated mainly in the context of a newly diagnosed MM; their prognostic significance remains largely intact in the course of therapy and disease (Pawlyn & Davies 2019). In addition, there are other factors such as MRD negativity and the duration of recurrence-free survival.

Modern flow cytometry and/or next-generation sequencing allow the detection of a residual plasma cell in 106 bone marrow cells (Kumar et al. 2016, Munshi et al. 2017, Flores-Montero et al. 2017, Kumar & Rajkumar 2018). Imaging techniques can be used. MRD negativity is associated with longer survival (PFS and OS) (Munshi et al. 2017, Lahuerta et al. 2017). Despite its prognostic significance, MRD diagnosis in multiple myeloma has no clinical relevance to date - however, the use of MRD detection for therapy control is under discussion (Kumar & Rajkumar 2018). It will be in use for endpoint control in studies testing new drugs.

When relapses occur, the duration of the response to the initial therapy, especially after autologous stem cell transplantation (ASCT), is an important prognostic factor. If recurrences occur early (12-18 months after ASCT), this is associated with an unfavourable prognosis - even if other high-risk factors are missing (Kumar & Rajkumar 2018).


Multiple Myeloma (MM): Prognosis calculation

Here you can access the prognostic calculation of the ISS score and the R-ISS score.

Multiple Myeloma - Therapy

Plasma cell myeloma: Therapy protocols with bortezomib improve prognosis in t(4;14) patients

Overall, new therapeutic developments have repeatedly significantly improved the prognosis of patients with multiple myeloma, with the introduction of proteasome inhibitors and immunomodulators alone increasing median survival by 4.7 years (Fonseca et al. 2017).

The therapeutic agents currently approved for the treatment of multiple myeloma can be assigned to six substance classes:

  • Chemotherapeutic agents: alkylants, anthracyclines, vinca alkaloids

  • Protease inhibitors

  • Immunomodulators

  • HDAC inhibitors

  • Monoclonal antibodies

  • Glucocorticoids

A large number of possible (combination) therapy regimens are available for treatment, so - also due to the high degree of heterogeneity of multiple myeloma - the therapy must be individually tailored to the patient, taking into account current guidelines and directives.

Bortezomib therapy protocols improve prognosis in t(4;14) patients with plasma cell myeloma

With therapy protocols containing bortezomib the very unfavourable prognosis for patients with t(4;14) could be improved (Avet-Loiseau et al. 2010, Chng et al. 2014, Merz et al. 2018). Patients with del(17p) also benefited from bortezomib when used before and after autologous stem cell transplantation (Neben et al. 2012, Merz et al. 2018). In the study by Merz et al., however, this effect was limited to patients without subclones - regardless of whether the subclonal aberrations were assigned to the high- or standard risk group.

However, the use of bortezomib in autologous stem cell transplantation did not lead to a prognostic improvement in patients with both t(4;14) and del(17p), which could be partially circumvented by autologous double stem cell transplantation and therapy regimens containing bortezomib (Cavo et al. 2013).

Patients with an NRAS mutation, but not patients with a KRAS mutation, responded less well to bortezomib, whereas no influence of the NRAS mutation on response and time to progression was demonstrated during therapy with dexamethasone (Mulligan et al. 2014).

BRAF V600E mutation: Predictor of good treatment response in early-stage multiple myeloma

The detection of a BRAF V600E mutation in early-stage multiple myeloma is associated with a good therapeutic response to alkylants, immunomodulators and protease inhibitors (Rustad et al. 2015). According to the current study situation, however, this does not lead to an improved prognosis (prolongation of PFS or OS). It remains to be seen to what extent a targeted therapy with the BRAF inhibitor vemurafenib will improve the prognosis. In any case, a targeted therapy modality exists.

Preliminary stop of clinical studies on the use of venetoclax in multiple myeloma

Good response rates with the BCL2 inhibitor venetoclax were observed for t(11;14) patients in relapse (Kumar et al. 2016; Moreau et al. 2017; Touzeau et al. 2017; Gonsalves et al. 2018, Pawlyn & Davies 2019). However, the inclusion of patients in studies on the use of venetoclax in relapsed/refractory multiple myeloma was stopped by the FDA for the time being because a Phase III study in the venetoclax arm had resulted in an increased number of deaths compared to the control arm (HR = 2.03) (FDA press release).

Recommendation

Due to “aspiration artifacts”, such as dilution by peripheral blood or focal infiltration, the actual plasma cell infiltration can be underestimated in the cytomorphological and flow cytometric assessment of bone marrow aspirates. According to recommendations of the European Myeloma Network (EMN), an additional bone marrow biopsy should therefore be performed (Caers et al. 2018). If discrepancies arise in the determination of plasma cell infiltration on biopsy and aspirate, the IMWG consensus is that the higher of the two values should be used (Rajkumar et al. 2014). Table 6 gives an overview of which examination methods the EMN recommends at which time points (selection according to Caers et al. 2018).

Table 6: Overview of diagnostic recommendations of the EMN at different examination times taking into account the examination material

(nach Caers et al. 2018)

Bone marrow

Date of examination

Method

Diagnosis

At response

At follow-up

At relapse

Bone marrow cytology and biopsy

mandatory

mandatory
(for patients in complete response*)

not required

mandatory
(for patients with light chain escape, oligosecretory disease)

Flow cytometry

recommended

optional

not required

optional

Cytogenetics using FISH

mandatory**

not required

not required

optional

Peripheral blood

Date of examination

Method

Diagnosis

At response

At follow-up

At relapse

Blood count and blood smear

mandatory

mandatory

mandatory

mandatory

NGS

optional

not required

not required

not required


* the definition of complete response (CR) includes a cytomorphological criterion (proportion of plasma cells in the bone marrow aspirate < 5%) (Kumar et al. 2016)

**  In any case the t(4;14) and del(17p) should be investigated, in addition it is recommended to detect/exclude the following aberrations: t(14;16), 1q21 gain, del(1p32)

Further plasma cell neoplasms

MGUS and SMM: Different symptoms but genetic similarities with multiple myeloma

Patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) do not exhibit the clinical symptoms of patients with multiple myeloma, but there are many similarities in genetic changes. It has been shown for various chromosomal aberrations that they were already present in the asymptomatic preliminary stage, but the frequency of the aberration increased as the disease progressed (Lopez-Corral et al. 2012).

MGUS

About 40% of patients with MGUS show a hyperdiploid chromosome set. Rearrangements involving the ICG locus are observed in about 30 - 40% of patients, with t(11;14) (19 - 22%), t(4;14) (2 - 3%) and t(14;16) (1-4%) being the most frequent translocations (Chiecchio et al. 2009, Bacher et al. 2010, Lakshman et al. 2018). For the rearrangements t(14;16) and t(14;20), which are associated with an unfavourable prognosis in patients with multiple myeloma, no prognostic relevance could be demonstrated in MGUS patients (Boyd et al. 2012). The incidence of 13q deletions is lower in MGUS (20%) than in multiple myeloma (45 - 58%).

The rate of progression in MGUS is approximately 1% per year, and the factors that promote progression are subject of current research. As observed for the SMM, for example, the aberrations del(17p) and t(4;14) are associated with an increased risk of progression (Merz et al. 2018, Lakshman et al. 2018). An elevated M protein level in the blood (M protein ≥ 1.5 g/dl) was also a factor mediating a risk of progression in the study by Merz et al. (Leukemia 2018).

Prognosis calculation

Here you reach the prognosis calculation of the MGUS prognosis score.

SMM

For patients with SMM, risk groups were defined in terms of progression to symptomatic myeloma depending on the most common chromosomal changes. For t(4;14) and del(17p), for example, it has been shown that they are associated with an increased risk of progression and that patients become more rapidly in need of treatment (Rajkumar et al. 2013). According to one study, this association also exists for 1q gains (Neben et al. 2013). Multiple trisomies in SMM are also associated with a shorter time to progression to symptomatic myeloma, but the prognostic significance of hyperdiploidy changes over the course of the disease is associated with a more favourable prognosis in patients with multiple myeloma (Neben et al. 2013). The del(13q) and t(11;14) have no significant influence on disease progression (Rajkumar et al. 2013). Accordingly, when diagnosing a SMM for risk classification, FISH analyses are recommended for the detection of 1q gains, the deletions 17p, 13q and 1p and the translocations t(11;14), t(4;14) and t(14;16) (Ghobrial et al. 2014).

Currently, there is no therapeutic indication for SMM. However, there is a controversial discussion in the literature whether SMM patients, especially in the high-risk group, could benefit from an early intervention (Kumar & Rajkumar 2018, Mateos & Gonzalez-Calle 2018, Kumar 2018). A study with 119 high-risk SMM patients (defined by specific M-protein levels, plasma cell fraction in bone marrow and the proportion of residual non-malignant plasma cells) showed that treatment with a lenalidomide and dexamethasone combination therapy resulted in delayed progression and improved survival compared to the observation cohort (Mateos et al. 2013). The treatment regime did not affect the efficiency of further therapies, if necessary due to progress (Kumar & Rajkumar 2018). Further studies are needed to evaluate the clinical benefit of early intervention in (high-risk) SMM, especially in light of the introduction of SLiM criteria and the advances in multiple myeloma diagnosis (Rajkumar et al. 2014, Kumar 2018). A large number of studies with this objective are currently being planned or conducted (Mateos & Gonzalez-Calle 2018).

You may also be interested in

Career

As a rapidly growing, innovative medical laboratory, we are always looking for bright minds to help us bring new and more effective therapies to patients around the world.

Learn more

Services

Do you have questions about sample submission, analyses performed or findings? Here you will find contact details, contact persons and our most frequently asked questions (FAQs).

Learn more

Quality management

We have been certified according to national and international standards since 2009 and have successfully maintained these accreditations.

Learn more